Is Buying Regenxbio Inc (RGNX) Here a Winning Strategy?

September 17, 2017 - By Richard Conner

The stock of Regenxbio Inc (NASDAQ:RGNX) is a huge mover today! The stock increased 5.21% or $1.4 on September 15, reaching $28.25. About 801,458 shares traded or 206.46% up from the average. Regenxbio Inc (NASDAQ:RGNX) has risen 51.43% since September 17, 2016 and is uptrending. It has outperformed by 34.73% the S&P500.
The move comes after 7 months positive chart setup for the $872.77M company. It was reported on Sep, 17 by We have $29.95 PT which if reached, will make NASDAQ:RGNX worth $52.37M more.

Wall Street await Regenxbio Inc (NASDAQ:RGNX) to release earnings on November, 8. Analysts forecast earnings per share of $-0.74, down exactly $0.05 or 7.25 % from 2014’s $-0.69 EPS. After posting $-0.47 EPS for the previous quarter, Regenxbio Inc’s analysts now forecast 57.45 % negative EPS growth.

Regenxbio Inc (NASDAQ:RGNX) Ratings Coverage

Among 4 analysts covering Regenxbio (NASDAQ:RGNX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Regenxbio had 4 analyst reports since October 12, 2015 according to SRatingsIntel. The stock has “Overweight” rating by Morgan Stanley on Tuesday, October 13. Piper Jaffray initiated Regenxbio Inc (NASDAQ:RGNX) on Monday, October 12 with “Overweight” rating. As per Tuesday, October 20, the company rating was initiated by Chardan Capital Markets. The firm earned “Buy” rating on Monday, October 12 by Bank of America.

More important recent Regenxbio Inc (NASDAQ:RGNX) news were published by: which released: “REGENXBIO to Present at Upcoming Investor Conferences” on August 31, 2017, also published article titled: “Rockville biotech buys Cambridge gene therapy firm for $86M”, published: “Regenxbio Inc. (RGNX) PT Raised to $75 at Chardan Capital Markets” on September 05, 2017. More interesting news about Regenxbio Inc (NASDAQ:RGNX) was released by: and their article: “Form 425 Dimension Therapeutics, Filed by: REGENXBIO Inc.” with publication date: September 01, 2017.

REGENXBIO Inc. is a clinical-stage biotechnology company. The company has market cap of $872.77 million. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. It currently has negative earnings. The Firm develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.